Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARB-1467
- Development stage
- Phase 2
- Lead developer
- Arbutus Biopharma
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
ARB-1467 (also known as ARB-001467 and TKM HBV) is a lipid nanoparticle (LNP) formulation containing three double-stranded small interfering RNAs (siRNAs). It was developed for the treatment of chronic hepatitis B virus (HBV) infection. The drug targets three distinct and highly conserved sites in the HBV genome to achieve post-transcriptional gene suppression of viral proteins generated from both covalently closed circular DNA (cccDNA) and integrated DNA. Its primary mechanism is RNA interference aimed at reducing all HBV transcripts and lowering all viral antigens, particularly hepatitis B surface antigen (HBsAg). This approach was intended to inhibit viral replication and potentially reawaken the immune system by reducing HBsAg levels. The drug was administered intravenously using proprietary LNP technology[1][5].
- Other names
- ARB-001467ARB001467ARB 001467TKM HBVARB 1468ARB1468ARB-1468
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on ARB-1467.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARB-1467.